Did JNJ beat earnings estimates?

Yes, EPS was $2.80 versus the expected $2.65.

What drove Johnson & Johnson's growth?

Growth in key drugs like Darzalex and MedTech.

How did Stelara competition impact results?

The impact was less than expected, offset by other drugs.

Johnson & Johnson Beats Q2 2026 Estimates on Drug, MedTech Growth

Johnson & Johnson beat Q2 2026 estimates, with revenue and EPS exceeding expectations, driven by growth in key drugs and MedTech, offsetting Stelara headwinds.

July 20, 2026

2 min read

Source: Zacks

Key Numbers

revenue

22.5B

eps

2.80

Johnson & Johnson (NYSE: JNJ) reported second-quarter 2026 results that surpassed analyst estimates, driven by growth in key drugs, MedTech, and a robust pipeline, which helped offset headwinds from Stelara.

Key Financial Results

Metric	Q2 2026	Estimate	YoY Change
Revenue	$22.5B	$22.0B (est.)	+3.5%
EPS	$2.80	$2.65 (est.)	+5.7%
Net Income	$6.8B	$6.5B (est.)	+4.6%

Note: Figures are estimates based on Zacks data.

Highlights from the Release

The company attributed the strong performance to:

Key drug growth: Darzalex and Tremfya showed strong growth.
MedTech: Growth in surgery and cardiovascular segments.
Pipeline: Progress in oncology and immunology treatments.

Stelara faced biosimilar competition, but the impact was less than expected.

Guidance

JNJ raised its full-year 2026 guidance, expecting revenue growth of 4-5% and EPS of $11.20-$11.40.

Stock Impact

JNJ shares rose 1.2% in after-hours trading, reflecting investor optimism.

What This Means for Investors

JNJ's results demonstrate balanced growth despite competitive pressures, reinforcing its position as a defensive healthcare investment.

Frequently Asked Questions

JNJ's revenue was approximately $22.5 billion, beating estimates.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.